Additionally, observed results were not related to Cas9 immunogenicity, as Ifngr1–/– B-ALL cells also significantly depleted in transgenic Cas9 mice transplanted with identical isogenic cell mixtures and treated with CAR-T therapy derived from transgenic Cas9 mice (Supplementary Fig. 4e). This evidence concerns the gene IFNGR1 and acute lymphoblastic leukemia.